1. Home
  2. TRAK vs KLRS Comparison

TRAK vs KLRS Comparison

Compare TRAK & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRAK

ReposiTrak Inc.

HOLD

Current Price

$8.08

Market Cap

138.9M

Sector

Technology

ML Signal

HOLD

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

N/A

Current Price

$6.30

Market Cap

144.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TRAK
KLRS
Founded
1990
2019
Country
United States
United States
Employees
N/A
20
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
138.9M
144.9M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
TRAK
KLRS
Price
$8.08
$6.30
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.00
AVG Volume (30 Days)
103.6K
80.5K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
1.00%
N/A
EPS Growth
20.69
N/A
EPS
0.18
N/A
Revenue
$21,007,076.00
N/A
Revenue This Year
$6.61
N/A
Revenue Next Year
$10.04
N/A
P/E Ratio
$44.22
N/A
Revenue Growth
4.84
N/A
52 Week Low
$6.94
$2.14
52 Week High
$23.72
$11.88

Technical Indicators

Market Signals
Indicator
TRAK
KLRS
Relative Strength Index (RSI) 53.60 43.62
Support Level $8.11 $5.26
Resistance Level $9.02 $7.18
Average True Range (ATR) 0.39 0.59
MACD 0.14 0.15
Stochastic Oscillator 69.37 47.09

Price Performance

Historical Comparison
TRAK
KLRS

About TRAK ReposiTrak Inc.

ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: